A Long-term Follow-up Study in Male Participants with X-linked Myotubular Myopathy Treated with ASP2957
X-linked myotubular myopathy is a rare genetic condition that causes severe muscle weakness, often making it difficult to breathe and move. This study is a long-term follow-up for males who have already received an investigational treatment called ASP2957 in an earlier clinical trial. Participants in this study will not receive any new medication. Instead, the medical team will monitor their health and development for up to five years. The main goal is to check for any delayed or ongoing side effects to ensure the treatment is safe over time. Doctors will also measure whether the treatment continues to help participants breathe more independently. They will record how many hours each day participants need breathing machines, known as ventilators. This helps researchers understand the lasting effects of the treatment and could guide future care for this condition.
نظرة سريعة
ما هو موضوع هذه الدراسة؟
X-linked myotubular myopathy (often shortened to XLMTM) is a rare inherited condition that affects the muscles used for movement and breathing. Because of a missing or faulty gene, muscles do not develop properly, leading to severe weakness from birth. Most boys with this condition need help from mechanical ventilators to breathe and require specialized, round-the-clock medical care.
In earlier clinical trials, researchers tested an experimental treatment called ASP2957 to see if it could help strengthen muscles and improve breathing. When developing innovative treatments, it is essential to watch how patients do over many years. This long-term study is designed specifically to follow up on participants who were already treated with ASP2957 in those earlier trials.
By following participants for up to five years, researchers hope to build a clear, complete picture of the treatment's long-term safety. They want to catch any unexpected side effects early and understand how the body responds over time. They will also look closely at daily breathing support needs to see if any improvements in muscle strength last as children grow.
النقاط الرئيسية
- This is a long-term follow-up study lasting up to five years.
- It is only for males who have already received the study drug ASP2957 in an earlier trial.
- No new medication or injections will be given during this study.
- Doctors will monitor ongoing safety and track daily ventilator use.
- Participation is voluntary, and families can withdraw at any time.
من قد يكون مؤهلاً؟
This study is open to males of any age who have a confirmed diagnosis of X-linked myotubular myopathy. Because the gene involved is linked to the X chromosome, this specific condition almost exclusively affects boys and men.
The most important requirement is that the participant must have already received the study treatment, ASP2957, as part of an earlier clinical trial. This study is not enrolling people who have never received this specific treatment before.
Families should speak with their hospital specialist or the study team to confirm eligibility. The study doctors will review previous medical records and trial participation details to make sure taking part remains safe and suitable.
هل يمكن أن تناسبك هذه الدراسة؟
أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.
- The participant is male.
- Has a confirmed diagnosis of X-linked myotubular myopathy (XLMTM).
- Previously received the investigational medicine ASP2957 in an earlier trial.
- Is able and willing to attend regular follow-up hospital visits for up to five years.
ماذا يتضمن المشاركة؟
Taking part in this study does not involve receiving any new medicine or injections. Instead, participants will attend scheduled hospital check-ups over a period of up to five years. During these visits, the study team will carry out standard health checks, such as physical examinations, blood tests, and heart monitoring. They will also carefully record any health problems or side effects experienced since the last visit. A key part of the study involves measuring breathing ability, so parents and caregivers will be asked to track the exact number of hours per day the participant uses a ventilator or breathing support machine.
المخاطر والفوائد المحتملة
المواقع (1)
- —غير مؤكدفرنسا
أسئلة شائعة
Will my child receive another dose of ASP2957 in this study?
No. This is a follow-up study only. It is designed to check the health and safety of participants who have already received the treatment in the past.
How long will our family be involved in this study?
The study monitors participants for up to five years after they received their initial treatment.
What is a ventilator, and why is it being tracked?
A ventilator is a machine that helps someone breathe. The researchers track daily ventilator hours to see if the treatment has helped the breathing muscles become stronger over time.
Do we have to pay to take part in this follow-up study?
No. Clinical trials in the UK do not charge participants. In many cases, travel expenses and related costs can also be reimbursed by the study sponsor.
Can we leave the study if it becomes too difficult to attend visits?
Yes. You are free to leave the study at any point. Your decision will not change the quality or availability of your child's regular medical care.
كيفية معرفة المزيد
تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.
نقاش
مناقشة المجتمع
مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.